According to our finding that PIR inhibitors can enhance anti‐tumor activity of CD8+ killer T cells by stimulating endogenous FAS expression and its membrane translocation in tumor, combination of PIR inhibitors and immune checkpoint blockade may be a potential strategy to the treatment of CRC, particularly those resistant to immunotherapy. This evidence concerns the gene CD8A and neoplasm.